Edward P. Gelmann, MD

Overview
Edward P. Gelmann, M.D. is the Deputy Director for Clinical Research in the Herbert Irving Comprehensive Cancer Center and at Columbia University Medical Center. Dr. Gelmann primarily cares for patients with genitourinary malignancies including prostate, testicular, bladder, and renal cell cancers.
Dr. Gelmann received his undergraduate degree from Yale College, B.S. magna cum laude, and later matriculated at Stanford University School of Medicine. Dr. Gelmann received his Internal Medicine training at the University of Chicago Hospitals and Clinics. He then joined the US Public Health Service to train as a fellow in Medical Oncology at the National Cancer Institute. After becoming an established researcher at the NCI by his work in the molecular biology of solid tumors, Dr. Gelmann moved to Georgetown University where he assumed the role of Chief of the Division of Hematology/Oncology. Dr. Gelmann has done clinical, early detection, and basic science research primarily in prostate cancer. His laboratory has made major contributions to our understanding of the genetic steps that transform a normal prostate cell to a cancer cell. Dr. Gelmann remains actively involved in pre- and postdoctoral education, teaching graduate students, house staff, and fellows.
Email: gelmanne@columbia.edu
Areas of Expertise / Conditions Treated
- Kidney Cancer
- Renal Cancer
Academic Appointments
- Clyde '56 and Helen Wu Professor of Medicine (Clinical Oncology)
- Professor of Pathology and Cell Biology (in the Herbert Irving Comprehensive Cancer Center)
- Professor of Pathology & Cell Biology at CUMC
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
Gender
- Male
Schedule an Appointment
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
Credentials & Experience
Education & Training
- Stanford University School of Medicine
- Residency: The University of Chicago Hospitals
- Fellowship: National Cancer Institute
Committees, Societies, Councils
Board Certifications
- Internal Medicine
- Medical Oncology
Honors & Awards
- 2007 Clyde Wu Professor of Oncology, Columbia University
- 2002 William M. Scholl Chair in Medical Oncology, Georgetown University School of Medicine
- 1992 Outstanding Visit Award, Department of Medicine, Georgetown University School of Medicine
- 1991 American Society for Clinical Investigation
- 1988 Unit Commendation, United States Public Health Service
- 1970 Phi Beta Kappa
Research
We have generated most of the data showing that NKX3.1 is a haploinsufficient suppressor gene that is inactivated in the majority of human prostate cancers. We currently are determining the mechanism of action of NKX3.1 and how it maintains differentiation, controls cell proliferation, and protects against DNA damage. We are also developing novel therapeutic targets in order to increase cellular levels of the protein to treat or prevent prostate cancer.
Research Interests
- Prostate cancer suppressor NKX3.1 and how loss of expression in prostate cells predisposes to cancer